--- title: "Foghorn Therapeutics Announces $50 Million Equity Financing" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/272287824.md" description: "Foghorn Therapeutics has announced a $50 million equity financing through agreements with leading life sciences investors, priced at a 30% premium to its closing share price. This financing, expected to close on January 13, 2026, will strengthen the company's balance sheet to approximately $208.9 million, extending its cash runway into the first half of 2028. The funds will support the advancement of its oncology pipeline, including trials for SMARCA4-mutant cancers. Analysts rate FHTX stock as a Buy with a $12.00 price target, though overall sentiment remains Neutral due to financial performance concerns." datetime: "2026-01-12T14:40:13.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/272287824.md) - [en](https://longbridge.com/en/news/272287824.md) - [zh-HK](https://longbridge.com/zh-HK/news/272287824.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/272287824.md) | [English](https://longbridge.com/en/news/272287824.md) # Foghorn Therapeutics Announces $50 Million Equity Financing ### Claim 70% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Foghorn Therapeutics ( (FHTX) ) has issued an announcement. On January 9, 2026, Foghorn Therapeutics announced that it had entered into purchase agreements with a group of leading life sciences investors, including BVF Partners, Deerfield Management and Flagship Pioneering, to raise approximately $50 million through the sale of common stock, pre-funded warrants and two series of premium-priced warrants, with the financing priced at a 30% premium to the company’s January 9 closing share price and expected to close on January 13, 2026. The transaction, conducted without an underwriter, strengthens Foghorn’s balance sheet to an estimated $208.9 million in cash, cash equivalents and marketable securities, extending its cash runway into the first half of 2028 and supporting continued advancement of its oncology pipeline, including the Phase 1 dose-escalation trial of FHD-909 (LY4050784) for SMARCA4-mutant cancers, and progression of its selective CBP and EP300 degrader programs toward key IND-related milestones in 2026, which collectively reinforce its positioning as a differentiated player in targeted cancer therapeutics. The most recent analyst rating on (FHTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Foghorn Therapeutics stock, see the FHTX Stock Forecast page. **Spark’s Take on FHTX Stock** According to Spark, TipRanks’ AI Analyst, FHTX is a Neutral. Foghorn Therapeutics’ overall stock score is primarily impacted by its weak financial performance and unattractive valuation. However, positive corporate events, including strategic partnerships and pipeline updates, provide some optimism for future growth. Technical analysis presents a mixed picture, with no strong trend direction. To see Spark’s full report on FHTX stock, click here. **More about Foghorn Therapeutics** Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression using its Gene Traffic Control platform. The company’s pipeline centers on first-in-class oncology programs, including SMARCA2-targeting agents, selective degraders of CBP and EP300, and other chromatin regulatory targets, with a particular focus on cancers such as non-small cell lung cancer, ER+ breast cancer, hematologic malignancies and other solid tumors with significant unmet medical need. **Average Trading Volume:** 215,413 **Technical Sentiment Signal:** Hold **Current Market Cap:** $295.8M Find detailed analytics on FHTX stock on TipRanks’ Stock Analysis page. ### 相關股票 - [Foghorn Therapeutics (FHTX.US)](https://longbridge.com/zh-HK/quote/FHTX.US.md) ## 相關資訊與研究 - [Foghorn Narrows Losses, Strengthens Cash Runway, Advances Cancer Pipeline](https://longbridge.com/zh-HK/news/278833687.md) - [Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 | FHTX Stock News](https://longbridge.com/zh-HK/news/272139716.md) - [Zymeworks Highlights New Ziihera Data to Broaden HER2 Cancer Reach](https://longbridge.com/zh-HK/news/279597854.md) - [New Preclinical Data on Anti-Tumor Effects of Nadunolimab in Metastatic Colorectal Cancer Presented at the Keystone Cancer Immunotherapy Conference](https://longbridge.com/zh-HK/news/279546672.md) - [AstraZeneca and Daiichi secure US fast-track status for cancer drug](https://longbridge.com/zh-HK/news/278343765.md)